{
  "abstract": "Checkpoint inhibitors best perform in neoadjuvant settings for a number of solid malignancies including cutaneous melanoma as compared with adjuvant schemes. A key difference between both treatment settings is the availability of tumor antigens to continuously prime antitumor T lymphocytes. Mounting evidence indicates that priming is a function chiefly performed by a subset of dendritic cells that cross-present tumor antigens rather than by malignant cells themselves. Acting in favor of these mechanisms to foster tumor-antigen priming is proposed to enhance the efficacy of adjuvant schemes.",
  "authors": [
    {
      "affiliations": [
        "Università degli Studi di Napoli Federico II, Napoli, Campania, Italy",
        "Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Italy"
      ],
      "name": "Paolo A Ascierto"
    },
    {
      "affiliations": [
        "Center for Applied Medical Research and Clinica Universidad de Navarra, University of Navarra, Pamplona, Navarre, Spain",
        "Nuffield Department of Medicine, University of Oxford, Oxford, UK"
      ],
      "name": "Ignacio Melero"
    }
  ],
  "title": "Reframing adjuvant immunotherapy in melanoma: all of it starts with priming",
  "uid": "6e340d7e-8dda-532a-ba06-04688c44a645"
}